Clinical trials: Depressive; Behavioral Disorder
Depression
Imaging Biomarkers for TMS Treatment of Depression
The purpose of this research is to learn more about how rTMS works to reduce the symptoms of depression. This information can be used to improve the effectiveness of the treatment.
- Trial name
- NCT01900314
- Testing
- repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan
Depressive Symptoms, Depression
Self-guided Treatment for Adolescents Navigating Depression
The goal of this study is to test whether an investigational mobile app can be a helpful treatment option for adolescents with symptoms of depression.
- Conditions
- Depressive Symptoms, Depression, Depressive Disorder, Depressive Episode
- Trial name
- NCT05462652
- Testing
- Active Intervention
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- Limbix Health, Inc.
Major Depressive Disorder, Nicotine Dependence
Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms
The primary purpose of this study is to determine whether, among smokers with elevated depressive symptoms, sequential antidepressant pharmacotherapy with fluoxetine (20 mg) begun 8 weeks prior to and extended throughout standard…
- Conditions
- Major Depressive Disorder, Nicotine Dependence, Depression
- Trial name
- NCT00578669
- Testing
- Fluoxetine, Dextrose
- Where
- United States
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- Butler Hospital
Major Depressive Disorder, Major Depressive Episode
Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder
The primary goal of the proposed study is to compare the effectiveness of universal school based screening for adolescent major depressive disorder to the current school process of targeted screening based on concerning behavior.
- Trial name
- NCT03716869
- Testing
- Universal Screening Arm
- Where
- United States
- Volunteers
- 12,909 people
- Sponsor
- Milton S. Hershey Medical Center
Major Depressive Disorder, Treatment Resistant Depression
Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients
The primary objective of the study is to evaluate the efficacy of Quetiapine extended release (XR) in combination with an selective serotonin reuptake inhibitor (SSRI) or Venlafaxine versus Lithium in combination with an…
- Trial name
- RUBY (NCT00789854)
- Testing
- Quetiapine XR, Lithium carbonate, SSRI/Venlafaxine
- Where
- 106 sites in Australia, Austria and 11 more
- Volunteers
- 688 people
- Sponsor
- AstraZeneca
Depression
iTBS for Adolescent Depression: An Open Label Study Evaluating Safety and Efficacy of Treatment
This is an open label, pilot, feasibility study evaluating effects of Intermittent Theta Burst Transcranial Magnetic Stimulation (iTBS) on 5 eligible adolescents for the treatment of depression.
- Trial name
- NCT04485455
- Testing
- iTBS Device/Motor Threshold Coil, iTBS Device/Treatment Coil
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of North Carolina, Chapel Hill
Depression
Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)
Trial to determine the maximum tolerated dose (MTD) based on safety and tolerability of MK-8777 (Org 26576, SCH 900777) in participants with major depressive disorder.
- Trial name
- NCT00610649
- Testing
- MK-8777
- Volunteers
- 54 people
- Sponsor
- Merck Sharp & Dohme LLC
Depression, Depressive Disorder
Mindful Breathing and tDCS for Depression
This study will investigate whether transcranial direct current stimulation (tDCS) targeting the dorsolateral prefrontal cortex (DLPFC) can enhance the therapeutic effect of mindful breathing training (MBT) for adolescent…
- Trial name
- NCT03897699
- Testing
- Transcranial Direct Current Stimulation, Mindful Breathing
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Minnesota
Major Depression, Cancer
Omega 3 FA Supplements as Augmentation in the Treatment of Depression
To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety symptoms in patients with select medical conditions…
- Conditions
- Major Depression, Cancer, Diabetes, Cardiovascular Diseases
- Trial name
- NCT01803711
- Testing
- Desvenlafaxine, Omega 3 Fatty acids
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- UConn Health
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111539
- Testing
- Escitalopram, Aripiprazole, Blinded capsule
- Where
- 62 sites in United States, Estonia and 7 more
- Volunteers
- 211 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
VA Augmentation and Switching Treatments for Improving Depression Outcomes
The overall purpose is to determine research based 'next-steps' for outpatients with major depressive disorder who have not had satisfactory outcomes to standard 'first-step' treatments.
- Trial name
- VAST-D (NCT01421342)
- Testing
- Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
- Where
- 35 sites in United States
- Volunteers
- 1,522 people
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder
Study of Neural Responses Induced by Antidepressant Effects
The proposed work aims to examine the neural changes associated with fast-acting antidepressant treatments in order to develop imaging-based biomarkers of treatment response for depression.
- Trial name
- SONRISA (NCT02674529)
- Testing
- Escitalopram, Real-time Neurofeedback fMRI task pre- and post-RCT
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Marta Peciña, MD PhD
Major Depressive Disorder, Treatment Resistant
Nuedexta in Treatment-Resistant Major Depression
There is an urgent need, therefore, to identify well-tolerated, orally available compounds that target the NMDA receptor as a novel treatment approach for TRD.
- Trial name
- NCT01882829
- Testing
- dextromethorphan/quinidine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- James Murrough
Major Depressive Disorder, Treatment Resistant Depression
Open-Label Safety Study of AXS-05 in Subjects With Depression
An open-label, long-term, safety study of AXS-05 in patients with major depressive disorder (MDD), including treatment resistant depression.
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, Depression
- Trial name
- NCT04039022
- Testing
- AXS-05 (dextromethorphan and bupropion) oral tablets
- Where
- 51 sites in United States
- Volunteers
- 876 people
- Sponsor
- Axsome Therapeutics, Inc.
Depression
Omega-3 for Depression and Other Cardiac Risk Factors - 2
The purpose of this 10 week randomized, placebo-controlled, double-blind clinical trial is to determine whether antidepressant augmentation with two grams of EPA omega-3 per day is superior to antidepressant therapy alone for…
- Trial name
- Omega-3(2) (NCT02021669)
- Testing
- Omega-3 supplement
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Washington University School of Medicine
Bipolar Disorder I or II
Tranylcypromine Treatment of Bipolar Depression
This study seeks to investigate whether tranylcypromine (Parnate®) might be an effective treatment of bipolar depression. New treatments are needed, as there is little evidence that standard antidepressants are effective in…
- Trial name
- NCT01430455
- Testing
- Tranylcypromine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- New York State Psychiatric Institute
Depressive Disorder, Major Depression
Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine
The study is a 6-week, proof-of-concept, open trial of vortioxetine for 20 patients with major depressive disorder.
- Conditions
- Depressive Disorder, Major Depression, Depression, Depression, Unipolar
- Trial name
- VOR-IISR (NCT02969876)
- Testing
- Vortioxetine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
The purpose of this study is to see if adding the study drug, ziprasidone, to an antidepressant medication helps improve symptoms of Major Depressive Disorder (MDD).
- Trial name
- NCT00633399
- Testing
- Ziprasidone
- Where
- 2 sites in United States
- Volunteers
- 458 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder Without Psychotic Features
Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression
This is a 6-week comparison of asenapine versus placebo as an add-on to ongoing antidepressant treatment in patients with major depression who have not had a complete therapeutic response to treatment with the antidepressant…
- Trial name
- NCT01670019
- Testing
- Asenapine 5-20 mg daily
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- Duke University
Major Depressive Disorder
Assessing Symptomatic Clinical Episodes in Depression
Randomized, Double-Blind, Active-Controlled Study of AXS-05 for MDD.
- Trial name
- ASCEND (NCT03595579)
- Testing
- AXS-05, Bupropion
- Where
- 4 sites in United States
- Volunteers
- 97 people
- Sponsor
- Axsome Therapeutics, Inc.